{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-26-000189","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2026-10-13T12:12:35+00:00","discovered_at":"2026-10-13T12:15:00.275621+00:00","generated_at":"2026-10-13T12:15:07.774750+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"medium","headline":"J&J Q3 sales $25.4B, up 5.9%; GAAP EPS $0.09 (-95.8%) on $5.78B other expense; adj EPS $2.59 (-7.5%)","bullets":["Q3 worldwide sales $25,399M vs $23,993M, +5.9% (operations +6.0%); U.S. +9.1% to $14,959M, international +1.5% to $10,440M.","Innovative Medicine sales $16,757M, +7.7%; MedTech $8,642M, +2.5%, with MedTech international up just 0.1%.","GAAP net earnings fell 95.9% to $210M and diluted EPS 95.8% to $0.09, driven by $5,780M of other (income) expense, net vs $(478)M income a year ago.","Adjusted net earnings $6,339M (-6.8%) and adjusted diluted EPS $2.59 vs $2.80 (-7.5%); adjusted effective tax rate 17.4% vs 19.4%.","R&D expense rose 26.7% to $4,652M and IPR&D impairments were $339M; nine-month worldwide sales $74,771M, +7.4%."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-26-000189","json":"https://secwatch.observer/filing/0000200406-26-000189.json","markdown":"https://secwatch.observer/filing/0000200406-26-000189.md","text":"https://secwatch.observer/filing/0000200406-26-000189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/0000200406-26-000189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/jnj-20261013.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T12:15:07.774750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}